Development of Prognostic Model Based on Five-gene Related to Tumor Mutation Burden in Hepatocellular Carcinoma

Zhou Shujun
Wuhan University Zhongnan Hospital

Qingling Li
Kunming medical university

Bin Yu
zhongnan hospital of wuhan university

Qifa Ye
Wuhan University Zhongnan Hospital

Yanfeng Wang (✉ yanfengwang@whu.edu.cn)
Wuhan University Zhongnan Hospital

Research

Keywords: Tumor mutation burden, prognostic model, hepatocellular carcinoma

Posted Date: November 17th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1010581/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Hepatocellular carcinoma (HCC), the incidence rate ranks sixth and regards as the second leading cause of cancer-related death in the world. Tumor mutation burden (TMB), a novel biomarker featured with microsatellite instability, has been thought to be closely related to tumor microenvironment and immunotherapy.

Methods

In this study, the 357 HCC samples were downloaded from The Cancer Genome Atlas (TCGA) and analyzed.

Results

Single nucleotide polymorphism (SNP) and C > T variation had the most missense mutations, and we also observed the higher mutation frequency in TP53, TTN, CTNNB1. With an optimal cut-off value of 4.61, the high level of TMB presented a worse prognosis. Functional analysis of the differentially expressed genes (DEGs) showed they were enriched in the pathway of the formation of extracellular matrix organization and sulfur compound metabolic. A 5-gene-based (including SFRP4, IL7R, FBLN2, COLEC10 and CHGA) model has been constructed to explore the independent prognosis capacity of each HCC patient.

Conclusions

The establishment of 5-gene-based prognosis model functions well in predicting the median of 1-, 3- and 5-year outcome of the individual patient and which will be beneficial for pre-clinical diagnosis and therapeutic decision-making.

Introduction

Hepatocellular carcinoma (HCC) has become the sixth most prevailing type of cancer and the second leading cause of cancer-related death in the world, accounting for a majority of the primary liver cancer\(^1\). Given the rapid progress and its multiple complications, most patients were diagnosed until the disease is in the middle-advanced stages. Moreover, a high-proportioned of patients with early-stage HCC experienced relapse after surgical interventions. The high mortality rate worldwide mirrors the difficulty in clinical diagnosis\(^2\). Tumor mutation burden (TMB) has been identified as a reliable indicator for immunotherapy effect, which provides a possible strategy in the most extensively studied pre-clinical field. TMB represents the total number of the substitution, insertion or deletion mutation for every megabase in the exon coding region\(^3\). It is a novel marker to forecast the benefit of the treatment of ICIs for a range of tumors, such as lung, endometrial, breast, and colorectal cancer\(^4-8\).

In spite of the connection between TMB and the immune microenvironment, as well as that between TMB and immunotherapy in HCC have been preliminarily investigated recently, the correlation between TMB and overall survival (OS) in patients remains unclear\(^9-11\). Additionally, due to the complexity and high cost of
sequencing, it is unlikely to be widely used in clinical evaluation of the efficacy of immunotherapy. Meanwhile, studies on HCC mentioned the relationship between TMB and specific genetic changes were mercifully rare.

The main objective of our research is to explore the potentially predictive value of TMB in terms of the OS of HCC patients, and investigate hub genes related to TMB levels. To predict the likelihood of OS rate of each individual in HCC patients, we identified 5 core genes related to TMB and correspondingly construct a 5-gene-based prognostic model. In addition, we provided an overview of the overall mutation profile in the HCC sample to explore new possibilities for individualized treatment.

Materials And Methods

2.1 Data download and processing

The public genomic and matched clinicopathological data related to HCC were downloaded from TCGA databases (https://portal.gdc.cancer.gov), and the genomic data format was FPKM. Some samples were removed due to the loss of data, 357 tumor samples were left to undergo further analysis. Similarly, the somatic mutation data of HCC were obtained from the TCGA databases and visualized with the “maftool” package in R software.

2.2 TMB calculation and grouping

TMB is the sum of substitutions, insertions, and deletions per megabyte in the exon in a tumor sample. So we calculated TMB by variants number/ the exon length (usually about 38 million) via Perl scripts (Table S1). X-tile was used to find the optimal cut-off value of TMB combined with patient OS rate, then defined anyone higher than the threshold as TMB-H, lower one as TMB-L (Figure S1).

2.3 Differentially expressed genes acquiring

Then we used the R package “limma” to process the data and screen out differentially expressed genes (DEGs) associate with TMB. All DEGs were identified using \(|\log_2 FC| > 1\) and false discovery rate (FDR) < 0.05, and the“pheatmap” package was utilized for hierarchical clustering.

2.4 Functional enrichment analysis of DEGs

The gene ontology (GO) pathway enrichment analysis and KEGG pathways analysis of DEGs were processed via R package “org. Hs. eg. db”. “clusterProfiler” and “ggplot2” package were used for annotation and drawing. Then, we conducted GSEA enriched GO to explore the underlying pathways significantly in two groups with \(p < 0.05\).

2.5 Construction of TMB Prognostic index (TMBPI)

The OS rate of DEGs was analyzed using the GEPIA database (http://gepia.cancer-pku.cn/). Then we screened out the hub genes according to logrank \(p < 0.05\). After that, we divided all the patients into high-
and low-risk groups based on the risk score (RS). K-M curves were applied to present the relationship between RS levels and OS. Finally, we drawn the survival receiver operating characteristic curve (ROC) and calculate the area under the curve (AUC) for assessing the value of prognosis model.

2.6 Statistical analysis

R Studio(https://www.rstudio.com) was used for the statistical analysis. OS was calculated by K–M and log-rank test methods. The comparison of continuous variables in two groups were performed by Student's t-test or one-way analysis of variance. \( p \text{ value} \leq 0.05 \), the difference was statistically significant.

Results

3.1 Overview of TMB in HCC

First of all, we assessed the mutations of each HCC sample in TCGA cohort to offer insights into the factors linked to HCC mutagenesis. We found that that SNP, missense mutations, and C > T mutation were most frequent varient type in HCC. C > T variation was the highest mutation type reached 15420 (Fig. 1). The last bar chart showed the top 10 mutated genes in HCC, and the results revealed that the variation of TP53, TTN, CTNNB1, MUC16, PCLO, and ALB, RYR2, ABCA13, MUC4, APOB (\( p \text{ value} < 0.001 \)) were higher.

3.2 Waterfall and interrelationship of top genes

In view of the MutSigCV algorithm, the waterfall diagram mapped and characterized the overview of HCC somatic mutations(Fig. 2A). Interrelationship plot was used to reveal the correlation between the expression of top 20 mutated genes, the results showed that the genes pairs of OBSCN and CTNNB1or FLG (\( p < 0.001 \)), LRP1B and TTN or APOB, MUC16 and SPTA1 or ABCA13 or RYR2, PCLO and CACNA1E or HMCN1, RYR2 and XIRP2, APOB and LRP1B, CSMD3 and FLG, LRP1B and CACNA1E, HMCN1 and SPTA1 (\( p < 0.05 \)) were co-expression. In addition, AXIN1 and CTNNB1 were mutually exclucised (\( p < 0.05 \))(Fig. 2B). 3.3 TMB and clinical relevance

X-tile was utilized to determine the optimal cut-off value at 4.61(Fig. S1). Then we divided 357 samples into TMB-H and TMB-L groups based on this value. The scatter chart showed the distribution of the two groups of data. The mean value of TMB-H group and TMB-L group are 8.19 and 2.79 (Fig. 3A). The results of K-M analysis showed that TMB was related to prognosis (\( p < 0.05 \)). Consistent with previous studies, patients with high TMB tend to have poor prognosis (Fig. 3B, \( p < 0.05 \)). As showed in Fig. 3C-E, the relationship between TMB and clinicopathological features including patients’ gender, age, and tumor grade (tumor cell differentiation) and TNM staging revealed that TMB was connected to N stage (\( p < 0.05 \)), age (\( p < 0.05 \)), and gender (\( p < 0.05 \)) in HCC patients. Older (age > 65) men without lymphatic metastasis tend to show higher TMB. But no association of TMB levels with other clinicopathologic characteristics was identified, such as T/M stage, clinical staging or grading(Figure S2).

3.4 Enrichment analysis for the DEGs
39 DEGs associated with TMB in all were identified (Table. S2). Fig. 4A showed the hierarchical clustering heatmap. The main biological process (BP), molecular function (MF) and cellular component (CC) associated with hub gene are presented in Fig. 4B. KEGG pathway analysis revealed that the DEGs were primarily enriched in the extracellular matrix organization, extracellular structure organization, sulfur compound biosynthetic process and sulfur compound metabolic process (Fig. 4C). The results of GSEA analysis revealed that RNA metabolic processes were enriched in TMB-H group, while other pathways including regulation of supramolecular fiber organization, regulation of organelle organization, positive regulation of organelle organization, actin filament organization, regulation of cytoskeleton organization, Actin polymerization or depolymerization, regulation of actin filament-based process and regulation of actin filament organization enrichment in TMB-L group (Fig. 4D).

3.5 Cox regression analysis

Analysis on OS demonstrated that hub genes (SFRP4, IL7R, FBLN2, COLEC10, and CHGA) (Fig. 5) in the model might be regarded as independent prognostic factors for HCC. Based on these five hub genes, univariate and multivariate cox regression analyses were utilized to establish a prognosis model, ROC was utilized to verify the accuracy of the model. We downloaded the transcriptome data from 357 HCC matched with clinical information by R package “merge”. Derived from the multivariate Cox regression model, we calculated the TMBPI as the following formula: PI = (0.08894538×SFRP4−0.00991219×COLEC10−0.00069051×CHGA−0.02461234×FBLN2−0.16547922×IL7R). The RS for each individual was obtained by TMBPI, and then we divided the sample into high and low-risk groups based on the median of the risk score (Table. S3). The AUC of 1-, 3- and 5-year survival rate were 0.64, 0.67 and 0.59 (Fig. 6B). And the results exhibited that the patients in the high-risk group tend to have a worse prognosis (P<0.001) (Fig. 6C).

Discussion

HCC is a highly aggressive disease and consistent with megascopic heterogeneity. Some studies have found that several signaling pathways are specifically disrupted in it. For instance, PI3K/AKT and IKK/NF-κB pathway were activated in HCC so that promote cell proliferation and induce epithelial-mesenchymal transformation17,18. In addition, the immune system takes a crucial part in tumor development. Marina et al. have observed that the activation of CTNNB1 pathway promoted immune evasion and drug resistance19. As a pivotal factor for the immune system to recognize and remove hepatoma cells, TMB affects the prognosis of patients before and after treatment a lot. Moreover, a significant correlation between TMB and the objective response rate has been observed in various cancers20. In present study, we found the missense mutation was the most frequent type in HCC. Studies have shown that missense mutations in TP53 differentiate HCC into different subtypes and may contribute to the progression of the disease21. SNP variants account for the vast majority in HCC, and in our study, the number of C > T variation reached 15,420, which is linked closely to the occurrence and development of HCC22,23.

Functional analysis results of TMB-associated DEGs showed they were mainly related to the extracellular matrix organization and sulfur compound metabolic process. Extracellular matrix is one of the components
of the immune microenvironment of HCC, some achievements have been made in the application of targeted drug delivery. The metabolism of elemental sulfur may be closely related to autophagy in HCC. Moreover, we found a distinctly inverse association between the activity of RNA metabolic process and TMB. An accumulating evidence pointed out the regulatory effect of different non-coding RNAs (ncRNAs) were obviously in various etiologies, including HBV, HCV and NAFLD, and eventually lead to HCC. This perhaps one of the most reason for the discouraging overall prognosis in TMB-H group.

Then we combined the TMB-associated DEGs and HCC patients’ OS rate for analysis. As the hub genes, SFRP4, IL7R, FBLN2, COLEC10 and CHGA were screened out which were reported to play an important role in HCC. SFRP4 is located in chromosome 7p14.1, it contains a cysteine-rich domain. This domain can regulate the Wnt signaling pathway by directly binding to Wnt thus form silencing complexes and suppress HCC. IL-7R have a place in T cell differentiation and lymphocyte development. The up regulation of IL-7R may active the intracellular pathways, induce expression of associated molecules, and promote the proliferation and migration of hepatoma cells. COLEC10 codes Collectin Liver 1 (CL-L1), a member of the C lectin family. Studies have shown that COLEC10 is regulated by miR-452-5p, promotes proliferation, invasion and migration in hepatoma cells. CHGA (or CGA) is highly expressed in HCC samples, previous study showed it can be used as an auxiliary diagnostic tool for HCC. In addition, risk model was introduced based on RS. This study showed significant statistics difference of prognosis between the FBLN2 high and low expression groups. However, the role of FBLN2 in liver cancer and its application value have not been reported, which may be a target worthy of exploration.

Based on the above 5 genes, multivariate Cox regression model analysis of specific overall probability was constructed in each patient. In the current study, we accurately predicted the possibility of OS in HCC patients. The AUC of 1-, 3- and 5-year survival rates were 0.64, 0.67 and 0.59 respectively. The model also showed a high degree of consistency when combined with the clinical data of our center. As far as we know, the joint analysis of five biomarkers, which have not been put forward before, will provide better clinical indications for patient to explore novel prognostic factors in HCC. Viewed from one perspective, our model dispense with identifying somatic mutations altogether in patients. Importantly, we aim to adopt a more efficient approach to significantly reduce the cost of sequencing and make hub gene-targeted sequencing technology more routine. Based on the expression of these five genes in patients, we intend to calculate the RS, which may prove useful in indicating patient outcomes for those who were not appropriate to undergo surgical treatments. Viewed from another perspective, accurate prognostic assessment is the crux of appropriate treatment. In routine clinical operation, pathological staging is essential for oncologists and patients to evaluate HCC prognosis. Due to lack of adequate clinical training for liver biopsies, a mass of patients had to be evaluated preoperatively by imaging (e.g., CT, MRI) or routine biochemical indexes (e.g., AFP, CEA, CA199). In this study, five biomarkers, less-invasive and more flexible, would be detected based on body fluid (e.g., blood, urine) to prognostic prediction. Meanwhile, it was the first time that TMB, DEGs with HCC clinical data are put together in our model for predicting patient outcomes. Utilizing molecular analysis combined with pathological staging would predict more accuracy than traditional systems for HCC patients in the era of precision medicine.
The substantial predictive ability and value of the genomic model for HCC patients should be recognized, we should also be aware of the several limitations in our study. First, unfortunately, no information about immunotherapy for each patient was retrieved in current study, which limited our study of TMB mediated changes in the HCC immune microenvironment. Additionally, because only a subset of the tumors in the TCGA project had both clinicopathological and TMB data available for analysis, the present object is limited to a small sample. Finally, lackness of information about the whole exon sequencing for HCC patients in our unit, We don't have much clinical data on our own to test this model. Thus, the efficiency of the prognosis model deserves more external validation using independent cohorts in the future.

**Conclusion**

In conclusion, we established a novel 5-gene-based prognosis model for outcome prediction for individual patient in HCC. This model might be a promising tool for risk stratification of prognosis in HCC. Furthermore, it provided a new idea for clinical diagnosis combined with pathological and molecular analysis of liver cancer.

**Abbreviations**

| Abbreviation | Description                |
|--------------|---------------------------|
| HCC          | Hepatocellular carcinoma  |
| TMB          | Tumor mutation burden     |
| TCGA         | The Cancer Genome Atlas   |
| SNP          | Single nucleotide polymorphism |
| DEGs         | Differentially expressed genes |
| OS           | Overall survival          |
| GO           | Gene ontology             |
| RS           | Risk score                |
| ROC          | Receiver operating characteristic curve |
| AUC          | Area under the curve      |
| BP           | Biological process        |
| MF           | Molecular function        |
| CC           | Cellular component        |
| ncRNAs       | non-coding RNAs           |
Declarations

Ethics approval and consent to participate: TCGA belong to public databases. The patients involved in the database have obtained ethical approval. Users can download relevant data for free for research and publish relevant articles. Our study is based on open source data, so there are no ethical issues and other conflicts of interest.

Consent for publication Not applicable.

Availability of data and materials The datasets obtained during the current study are available in the TCGA repository, [https://portal.gdc.cancer.gov].

Competing interests The authors declare that they have no competing interests.

Funding This work was supported by the Health Commission of Hubei Province Scientific Research Project (grant number: WJ2021Z005).

Authors' contributions Shujun Zhou designed and mainly executed this project. Qingling Li finished writing and modifying the R language code, and was a major contributor in writing the manuscript. Bin Yu, Qifa Ye and Yanfeng Wang guided the idea of the project and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments We acknowledge TCGA database for providing their platforms and contributors for uploading their meaningful datasets.

References

1 Desai, A., Sandhu, S., Lai, J. P. & Sandhu, D. S., Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol 11 1 (2019).

2 Kamiyama, T. et al., Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. WORLD J SURG ONCOL 10 107 (2012).

3 Huang, D. et al., Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer. TARGET ONCOL 15 93 (2020).

4 van den Bulk, J., Verdegaal, E. M. & de Miranda, N. F., Cancer immunotherapy: broadening the scope of targetable tumours. OPEN BIOL 8 (2018).

5 Hsu, Y. C. et al., Tumor mutation burden and recurrent tumors in hereditary lung cancer. Cancer Med 8 2179 (2019).

6 Lee, D. W. et al., Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. CLIN CANCER RES 25 6141 (2019).
7 Riggs, M. J. et al., DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. PLOS ONE 15 e244558 (2020).

8 Jang, B. S., Han, W. & Kim, I. A., Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer. RADIOTHER ONCOL 142 202 (2020).

9 Steuer, C. E. & Ramalingam, S. S., Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? J CLIN ONCOL 36 631 (2018).

10 Yu, Q. J., Liang, Y. Z., Mei, X. P. & Fang, T. Y., Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma. EXCLI J 19 861 (2020).

11 Cai, H. et al., Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. J SURG ONCOL 121 1007 (2020).

12 Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P., Maftools: efficient and comprehensive analysis of somatic variants in cancer. GENOME RES 28 1747 (2018).

13 Walter, W., Sanchez-Cabo, F. & Ricote, M., GOplot: an R package for visually combining expression data with functional analysis. BIOINFORMATICS 31 2912 (2015).

14 Tang, Z. et al., GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. NUCLEIC ACIDS RES 45 W98 (2017).

15 Robinson, M. D., McCarthy, D. J. & Smyth, G. K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. BIOINFORMATICS 26 139 (2010).

16 Xie, F. et al., Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. INT IMMUNOPHARMACOL 89 107135 (2020).

17 Wu, L., Zheng, J., Chen, P., Liu, Q. & Yuan, Y., Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway. BIOMED PHARMACOTHER 90 705 (2017).

18 He, G. & Karin, M., NF-kappaB and STAT3 - key players in liver inflammation and cancer. CELL RES 21 159 (2011).

19 Ruiz, D. G. M. et al., beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. CANCER DISCOV 9 1124 (2019).

20 Yarchoan, M., Hopkins, A. & Jaffee, E. M., Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377 2500 (2017).
21 Tanaka, S. et al., Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. CANCER RES 53 2884 (1993).

22 Toshikuni, N., Matsue, Y., Minato, T., Hayashi, N. & Tsutsumi, M., Association between transforming growth factor-beta1 -509 C>T variants and hepatocellular carcinoma susceptibility: a meta-analysis. NEOPLASMA 63 961 (2016).

23 Sghaier, I. et al., TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. Br J Biomed Sci 76 35 (2019).

24 Zhang, L. Y. et al., Targeting Tumor Immunosuppressive Microenvironment for the Prevention of Hepatic Cancer: Applications of Traditional Chinese Medicines in Targeted Delivery. CURR TOP MED CHEM 20 2789 (2020).

25 Wang, S. S. et al., Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway. CELL DEATH DIS 8 e2688 (2017).

26 Wong, C. M., Tsang, F. H. & Ng, I. O., Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol 15 137 (2018).

27 Yao, Z. et al., ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. MOL ONCOL 11 422 (2017).

28 Wu, J. et al., Bioinformatic Analysis of Circular RNA-Associated ceRNA Network Associated with Hepatocellular Carcinoma. BIOMED RES INT 2019 8308694 (2019).

29 Wu, Q. et al., Tumor suppressor role of sFRP4 in hepatocellular carcinoma via the Wnt/betacatenin signaling pathway. MOL MED REP 23 (2021).

30 Zenatti, P. P. et al., Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. NAT GENET 43 932 (2011).

31 Kong, F. et al., Hepatitis B virus X protein promotes interleukin-7 receptor expression via NF-kappaB and Notch1 pathway to facilitate proliferation and migration of hepatitis B virus-related hepatoma cells. J Exp Clin Cancer Res 35 172 (2016).

32 Zhang, B. & Wu, H., Decreased expression of COLEC10 predicts poor overall survival in patients with hepatocellular carcinoma. CANCER MANAG RES 10 2369 (2018).

33 Zheng, J. et al., MiR-452-5p mediates the proliferation, migration and invasion of hepatocellular carcinoma cells via targeting COLEC10. Per Med 18 97 (2021).

34 Spadaro, A. et al., Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 11 1987 (2005).
Figures

Figure 1
Overview of TGCA HCC cohort mutations.

Figure 2
The expression of mutated genes in each sample and their correlation. (A) The mutations of the top 30 genes in each sample with waterfall plot in the TCGA HCC cohort. (B) interrelationship of the top 20 mutated genes in TCGA HCC cohort.
Figure 3

Survival rate and clinical correlation analysis. (A) The distribution of TMB among each group. (B) K–M curves of the TMB-H and TMB-L groups. (C) Wilcoxon test for patients stratified by N stage. (D) Wilcoxon test for patients stratified by age. (E) Wilcoxon test for patients stratified by gender.
Figure 4

The expression status of DEGs in each group and GO, KEGG, GSEA analysis. (A) Heatmap of DEGs between TMB-H and TMB-L patients. (B) Functional analysis of the enriched biological processes (BPs), cell composition (CC), and molecular function (MF) of GO analysis. (C) KEGG enrichment diseases analysis. (D) Gene set enrichment analysis between TMB-H and TMB-L groups.
Figure 5

K-M survival analysis of SFRP4(A), LI7R(B), FBLN2(C), CHGA(D) and COLEC10(E).
Figure 6

Construction of the five-gene prognostic model. (A) The stratification of the risk score, the survival status of patients, and heatmap of the 5 genes. (B) time-dependent ROC analysis for predicting the overall survival of patients using the risk score. (C) K-M survival analysis.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalFiles1.pdf
- SupplementalFiles2.pdf
- TableS1.xlsx
- TableS2.xlsx